Corrections to an Article By Peter Kennedy, MD

Axillary dissection was more likely to be omitted among patients in the ALTERNATE trial when there was 1 positive sentinel node compared with 2 or more.

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Of the 4 patients with relapsed/refractory multiple myeloma who received KLN-1010, 1 complete response and 3 partial responses were achieved at varying levels of MRD sensitivity.

Prior bendamustine exposure correlated with worse complete response rates with axi-cel among those with relapsed/refractory follicular lymphoma.